Travatrelvir, an Inhibitor of SARS-CoV-2 Main Protease now in Phase 1 Clinical Trials: in vitroDrug Resistance Compared to Nirmatrelvir

May 28

Written By Maria Parshenkova

Download Poster

Maria Parshenkova

Risk/Benefit Profiles of Currently Approved Oral Antivirals forTreatment of COVID-19: Similarities and Differences